CD38-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


«12...3456789101112131415»
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK
    Clinical, Review, Journal:  The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma. (Pubmed Central) -  Jan 7, 2021   
    Belamaf is also associated with frequent corneal ocular adverse events, which represents a unique toxicity in multiple myeloma therapeutics, and its administration requires a multidisciplinary approach with oncologists and eye care specialists to safely and effectively manage patients on belamaf therapy. In this review, we discuss the preclinical and clinical data leading to the regulatory approval of belamaf, the monitoring and mitigation strategies of corneal ocular adverse events, and its current and future role in the RRMM treatment landscape.
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK
    [VIRTUAL] Immunotherapy in Multiple Myeloma - Live Q&A (Live) -  Dec 2, 2020 - Abstract #ASH2020ASH_5805;    
    Some of these cell surface antigens are also internalized, making them ideal candidates for antibody–drug conjugates (ADC) such as belantamab mafodotin, conjugated with auristatin F and targeting BCMA...Bispecifics targeting the MM antigens BCMA and GPRC5d have already demonstrated deep and durable responses in heavily pretreated patients. Bispecifics targeting CD38 and FCHR5 as well as trispecifics are under investigation.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal, IO Biomarker:  T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. (Pubmed Central) -  Nov 25, 2020   
    Cytokine release syndrome is the most common adverse event, which can be adequately managed with tocilizumab or steroids...GPRC5D, CD38 and FcRH5), are also evaluated in early phase clinical trials. Such bispecific antibodies, targeting other antigens, may be given to patients with low baseline BCMA expression, disease with substantial heterogeneity in BCMA expression, following prior BCMA-targeted therapy, or combined with BCMA bispecific antibodies to prevent development of antigen escape.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    [VIRTUAL] A Systematic Review of Daratumumab Based Four Drug Regimen for Newly Diagnosed Multiple Myeloma in Phase III Clinical Trials () -  Nov 5, 2020 - Abstract #ASH2020ASH_5359;    
    (2019) studied the efficacy of Dara + bortezomib (V) + thalidomide (T) + dexamethasone (d) vs VTd in newly diagnosed MM (NDMM) pts (n=1085) in CASSIOPEIA phase III trial...(2018) reported the role of Dara + V + melphalan (M) + prednisone (P) vs VMP in NDMM pts (n=706) in a phase III trial (Alcyone)... NDMM treatment with Dara in four-drug regimens (VTd, VMP, VRd) has shown promising outcomes with improved efficacy and higher negative MRD status, providing a benchmark for future studies.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    [VIRTUAL] Systematic Review of Phase III Trials of Daratumumab Based Regimens in Relapsed Refractory Multiple Myeloma () -  Nov 5, 2020 - Abstract #ASH2020ASH_5325;    
    (2019) studied the role of Dara + bortezomib (V) + dexamethasone (d) in RRMM pts (n=498) in phase III trial (CASTOR)...(2019) underlined the efficacy of Dara + carfilzomib (K) and (d) in RRMM pts (n=466) in phase III trial (CANDOR), and Nizar J. Bahlis et al... Treatment of RRMM with Dara plus standard care therapy (Vd, Rd, and Kd) has shown promising outcomes with improved efficacy and higher negative MRD status, providing a new benchmark for future studies.
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides
    [VIRTUAL] HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics—Subgroup Analysis (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_4035;    
    P2
    Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells...Methods : Patients with RRMM had received ≥2 lines of prior therapy, including an IMiD and a proteasome inhibitor, and were refractory to pomalidomide and/or an anti-CD38 monoclonal antibody...The safety profile of melflufen plus dex in patients with HR cytogenetics was consistent with that of the overall population. Taken together, these data support further evaluation of melflufen plus dex in RRMM with HR cytogenetics.
  • ||||||||||  Melflufen (melphalan flufenamide) / Oncopeptides
    [VIRTUAL] HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)—Subgroup Analysis (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_4012;    
    P2
    2019;102:389), and outcomes are considerably worse than those for pts without EMD; for example, a recent analysis of isatuximab + pomalidomide + dex showed a median progression free survival (PFS) of 4.6 mo vs 11.5 mo in the total population (Beksac et al...Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells...To date, this clinical study provides the largest cohort of pts with EMD demonstrating benefit in this population with a high unmet medical need. These data support further evaluation of melflufen + dex in RRMM with EMD.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    [VIRTUAL] A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3986;    
    We here developed and determined in preclinical models of human MM the efficacy of VIS832, a novel humanized monoclonal antibody (MoAb) with differentiated CD138 target binding to the anti-CD138 MoAb BB4 within indatuximab ravtansine (BT082)...Evaluation of VIS832-induced ADCC in NK-MM cell co-cultures determined its EC50 values ranged from 2.22 + 0.37 to 15.3 + 2.71 ng/ml, with % maximal lysis of 37.06 + 1.45 % to 97.3 + 3.34 %, across tested MM cell lines (n=12), both sensitive or resistant to current therapies including dexamethasone, IMiDs, and bortezomib...VIS832 induced higher maximal lysis (~3-fold) of all target MM cell lines than CD38-targeting daratumumab (dara), regardless of resistance to lenalidomide and pomalidomide...Taken together, the significant in vivo efficacy of VIS832, coupled with its mechanisms of action and potent in vitro MM cytotoxicity, strongly support clinical development of VIS832, as monotherapy and in combination, to overcome multidrug resistance and improve patient outcome in MM. Once its efficacy is established in RRMM, its favorable therapeutic index should allow for moving rapidly to earlier stages of disease, newly diagnosed MM and smoldering MM.
  • ||||||||||  Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
    [VIRTUAL] Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3669;    
    With the exception of Gemtuzumab ozogamycin, an anti-CD33 antibody drug conjugate, the landmark success of immunotherapy in other hematologic malignancies has not translated to AML...However, we discovered strong staining of endothelial cells throughout multiple organ systems. CD93 expression was confirmed on endothelial cell lines iHUVEC and TIME, and CD93 CAR T cells produced cytokines when co-cultured with these endothelial cells.
  • ||||||||||  [VIRTUAL] CD22 Gating for Flow Cytometric Analysis in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after CD19 CAR-T Therapy (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_2927;    
    In conclusion, our data on the comparison between CD22 and cCD79a expression in CD19 negative relapsed B-ALL patients revealed that, under most circumstances (with 82.5%-91.7% chance), CD22 gating alone could efficiently identify B cells in patients after CD19 CAR-T therapy, which is also a cost-effective and labor-saving strategy for routine practice compared to cCD79a gating. In case of partial or dim CD22 expression, the cCD79a gating is needed.
  • ||||||||||  Darzalex IV (daratumumab) / J&J, Mozobil (plerixafor) / Sanofi
    [VIRTUAL] Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_2826;    
    Nevertheless, our findings are consistent with inferior mobilization outcomes reported in the DARA-containing arms of phase 3 trials of triplet induction +/- DARA and highlight the nearly universal requirement for plerixafor usage when DARA is administered within a month prior to apheresis. Prospective study of day 4 pre-harvest peripheral blood CD34 counts and other predictors of stem cell yield should be incorporated into future clinical trials of CD38 monoclonal antibody-based induction regimens for transplant-eligible MM pts.